Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e253661ef0079638605fe5e327287a8f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
filingDate |
2016-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8aba0e41fd66ddf6f72e20d43d50cdb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cb3d43513382330a75c00fa05dd412f |
publicationDate |
2016-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2016162537-A1 |
titleOfInvention |
Induction dosing regimen |
abstract |
The invention relates to a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNFα antibody which ranges from 161 to 320 mg such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11684677-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667719-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11623952-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10633438-B2 |
priorityDate |
2015-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |